| Methods |
Randomised controlled trial
Blinding: both patients and outcome assessor were blinded.
Loss to follow‐up: none
Appropriate statistical analysis: yes, intention to treat. |
| Participants |
25 patients Inclusion criteria: Supraspinatus tendonitis defined as a clinical entity of tenderness over the supraspinatus tendon, pain on resisted abduction and normal passive gleno humeral range.
Exclusion criteria: past history or clinical evidence of inflammatory arthritis |
| Interventions |
Group 1(12 patients): affected supraspinatus tendon injected with 80mg methylprednisolone diluted in 2 ml 2% lignocaine (a total of 4 ml)
Group 2(13 paitents): Placebo injection 4ml 0.9% normal saline at the same site.
All patients encouraged to move shoulders through full range of movement in subsequent days but no formal physiotherapy |
| Outcomes |
Assessed at baseline, 2 and 8 weeks
1) Pain on 10cm VAS
2) Paracetomol count |
| Notes |
Met inclusion crieria of review but insufficient data presented (ie. no measure of variance or data from which it could be calculated), therefore not included in meta‐analysis.
Reported no difference in improvement in pain or analgesic consumption between the two groups at 2 and 8 weeks of follow‐up. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
